SecBot SecBot
8-K ·Filed Apr 24, 2026

APGE

Apogee Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-177288
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor upcoming proxy filings for any disclosure of new board appointments or changes in governance structure. Absent unexpected leadership shifts, this event is routine and unlikely to impact trading dynamics.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$86.47
T+0 close · Apr 24, 2026 · via day close
Latest settled
+55.06%
T+60 · $134.08
Vs SPY
+50.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $86.47entry
  2. T+1 · 7mo ago −1.27%α −0.79% · $85.37
  3. T+5 · 7mo ago −3.38%α −3.78% · $83.55
  4. T+20 · 6mo ago −4.23%α −9.19% · $82.81
  5. T+60 · 4mo ago +55.06%α +50.28% · $134.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics announced the resignation of two board members, Andrew Gottesdiener, M.D. and Peter Harwin, effective May 11, 2026. The departures are not due to disagreements with the company, and the board will be reduced from nine to seven members.

Key Facts

  • Andrew Gottesdiener, M.D. and Peter Harwin resigned from the board effective May 11, 2026
  • Resignations were not due to disagreements with the company
  • Board size reduced from nine to seven directors
  • No immediate replacements named

Financial Impact

No direct financial impact disclosed

governanceboard composition

Risk Factors

  • Potential governance instability if key board committees lose members
  • Market perception risk if no replacements are named in a timely manner

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-177288
Document: 0001193125-26-177288-index-headers.html0001193125-26-177288
Document: 0001193125-26-177288-index.html0001193125-26-177288
Document: 0001193125-26-177288.txt0001193125-26-177288

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens in 8h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026